Viatris (VTRS)
(Delayed Data from NSDQ)
$11.89 USD
-0.01 (-0.08%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $11.90 +0.01 (0.08%) 5:20 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
Price, Consensus and EPS Surprise
VTRS 11.89 -0.01(-0.08%)
Will VTRS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VTRS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VTRS
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss
VTRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viatris (VTRS) Q2 Earnings Surpass Estimates
DocGo Inc. (DCGO) Q2 Earnings and Revenues Miss Estimates
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
Other News for VTRS
Viatris Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress
Davis New York Venture Fund Fall Review 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Why Bargain-Priced Viatris Could Deliver Strong Returns
Glenview Capital's Q2 moves include selling Broadcom after just one quarter, exiting Meta